Model-based prediction of nanoparticle and dissolved form ratios using total concentration data: a case study of SNB-101.

ABSTRACT:

Introduction

Irinotecan (CPT-11), a topoisomerase I inhibitor, serves as a prodrug for SN-38, its active metabolite with significantly higher cytotoxic potency. Despite its clinical efficacy, irinotecan's therapeutic potential is limited by low fraction of conversion to SN-38, inefficient tumor targeting, and dose-limiting toxicities such as diarrhea and neutropenia. Nanoparticle-based formulations, such as SNB-101, offer a promising solution by encapsulating irinotecan and SN-38, enhancing solubility, improving drug delivery efficiency, and reducing systemic toxicity through tumor-specific accumulation via the enhanced permeability and retention (EPR) effect.

Methods

This study aimed to develop a pharmacokinetic (PK) model to differentiate between nanoparticle (NP) and diss

SUBMITTER: Park J 

PROVIDER: S-EPMC12408558 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature